Joint effects of the CYP1A1 MspI, ERα PvuII, and ERα XbaI polymorphisms on the risk of breast cancer: Results from a population-based case-control study in Shanghai, China

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 2, 2006, Pages 342-347

  Shen, Yueping ^a,b   Li, De Kun ^c   Wu, Junqing ^b   Zhang, Zibao ^b   Gao, Ersheng ^b  

^a SOOCHOW UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^c DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ONCOPROTEIN; PROTEIN MSPL; PROTEIN PVUII; PROTEIN XBAI; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CHINESE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ONSET AGE; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADULT; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 CYP1A1; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33644761666     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0485     Document Type: Article

References (37)

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol. VII. Lyon (France): IARC; 2003. p. 603-8.
2. Fan J, Devesa SS, Chow WH, et al. Cancer incidence trends in urban Shanghai, 1972-1994: an update. Int J Cancer 1999;83:435-40.
3. Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin 1999;49:138-44.
4. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
5. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48-65.
6. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988;48:246-53.
7. Service RF. New role for estrogen in cancer? Science 1998;279:1631-3.
8. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997;94:10937-42.
9. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
10. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-77.
11. Andersen TI, Heimdal KR, Skrede M. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-70.
12. Shin A, Kang D, Nishio H, et al. Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2003;80:127-31.
13. Cai Q, Shu XO, Jin F, et al. Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2003;12:853-9.
14. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk factor individuals to lung cancer by DNA polymorphism of the cytochrome P4501A1 gene. FEBS Lett 1990;263:131-3.
15. Garcia T, Sanchez M, Cox JL, et al. Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acids Res 1989;17:8364.
16. Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis on estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995;87:446-51.
17. Davis DL, Bradlow HL, Wolff ML, et al. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 1993;101:372-27.
18. Dewailly E, Dodin S, Verreault R, et al. High organochlorine body burden in women with estrogen receptor-positive breast cancer. J Natl Cancer Inst 1994;86:232-4.
19. Krieger N, Wolff MS, Hiatt RA, et al. Breast cancer and serum organochlorines: a prospective study among White, Black, and Asian women. J Natl Cancer Inst 1994;86:589-99.
20. Romieu I, Berlin JA, Colditz G. Review and meta-analysis. Oral contraceptives and breast cancer. Cancer 1990;66:2253-63.
21. Taioli E, Trachman J, Chen X, et al. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55:3757-8.
22. Ambrosone CB, Freudenheim JL, Graham S, et al. Cytochrome P450A1 and glutathione s-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995;55:3483-5.
23. Huang CS, Chern HD, Chang KJ, et al. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-5.
24. Huang CS, Shen CY, Chang KJ, et al. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer 1999;80:1838-43.
25. Wen W, Cai Q, Shu XO, et al. Cytochrome P450 1B1 and catechol-O- methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the Shanghai Breast Cancer Study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14:329-35.
26. Nishio H, Hayashi C, Lee MJ, et al. Itai-itai disease is not associated with polymorphisms of estrogen receptor α gene. Arch Toxicol 1999;73:496-8.
27. Weir BS. Genetic data analysis II: methods for discrete population genetic data. Sunderland (MA): Sinauer Association, Inc., Publishers; 1996.
28. Breslow NE, Day NE. Statistical methods in cancer research. Vol I. The analysis of case-control studies. Lyon (France): IARC; 1980.
29. Bailey LR, Roodi N, Verrier CS, et al. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
30. Ishibe N, Hankinson SE, Colditz GA, et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res 1998;58:667-71.
31. Miyoshi Y, Takahashi Y, Egawa C, et al. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J 2002;8:209-15.
32. Petersen DD, McKinney CE, Ikeya K, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991;48:720-5.
33. Landi MT, Bertazzi PA, Shields PG, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994;4:242-6.
34. Parl FF, Cavener DR, Dupont WD. Genetic DNA analysis of the estrogen receptor gene in breast cancer. Breast Cancer Res Treat 1989;14:57-64.
35. Yaich LY, Dupont WD, Cavener DR. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 1992;52:77-83.
36. Mitrunen K, Kataja V, Eskelinen M, et al. Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics 2002;12:67-72.
37. Zheng SL, Zheng W, Chang BL. Joint effect of estrogen receptor β sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res 2003;63:7624-9.